What's the geno type for these trials
Hi there
This term "pangenotypic" refers to all 6 genotypes.
Peace
Deb
Wow! Here we go. Everyone who has HCV will get treated. No one needs to die from this anymore. The creator of the "Simpson's" just died from it though due to the stigma they are keeping it hush. He was from my city.
This is very good news. Thanks for posting! No one should wait to be cured and everyone needs to be tested.
Hi KOKO
Yep, they are getting closer to wiping this nasty virus off the face of this big blue planet!.......just as it should be right!
Hopeful for everyone
Deb
Unfortunately they won't hit the US market this summer. Breakthrough status has been recinded.
http://www.forbes.com/sites/greatspeculations/2015/03/13/these-two-catalysts-can-move-mercks-stock-up/
Excerpts March 13, 2015
Merck has been looking to get a breakthrough in Hepatitis C market, but its clinical trials haven’t seen the expected success
Read more at link
The company is now focusing on clinical trials of combination of MK-5172 and MK-8742, and may file the new drug application soon. However, it has lost breakthrough therapy designation for these drugs.
JM, MK-5172 is Grazoprevir, and MK-8742 is Elbasvir. These are the meds I took, combined 100 mg/50 mg in one tablet. I don't know what "expected success" means, but according to presentations @ the EASL meetings in 2014, the SVR rate for 1a GT, both tx experienced and not, cirrhotic or not, was 94%. GT 1b patients, regardless of prior tx or cirrhosis, SVR was 99%. Getting the breakthrough designation is a formality and good for advertising, but is no reflection on the drug's efficacy. As Gilead beat Merck to the punch, so to speak, there went the "breakthrough" designation. I doubt any of Gilead's meds are any better, and the Merck relapse rate of 1% is going to be pretty hard to beat. As far as unexpected side efx, it is still early in the game to be as certain. mac790
Good luck to you Mac. Know you've been fighting for SVR and you've gotta hit the mark. Let us know what's ahead.
.....Kim
Sorry I didn't explain more. The trial results for shorter duration didn't have the sucess. Once the phase 3 trials 12 week trials are complete then Merck can resubmit and it's looking real good. I just wanted to mention not to expect FDA approval this summer. If all is good most likely it will be near the end of thid year or early 2016 for the US.
Best wishes for achiving SVR